PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2570065-4 1989 The Glu-204 and Phe-224 mutant DAOs showed comparable enzyme activities to that of the wild type enzyme, and were inhibited strongly by sodium benzoate, a potent competitive inhibitor of DAO. Sodium Benzoate 136-151 D-amino acid oxidase Homo sapiens 31-34 34294612-10 2021 Our recent study found that an NMDAR enhancer, sodium benzoate (the pivotal inhibitor of D-amino acid oxidase (DAAO)), improved the cognitive and global function of patients with early-phase AD. Sodium Benzoate 47-62 D-amino acid oxidase Homo sapiens 89-109 34294612-10 2021 Our recent study found that an NMDAR enhancer, sodium benzoate (the pivotal inhibitor of D-amino acid oxidase (DAAO)), improved the cognitive and global function of patients with early-phase AD. Sodium Benzoate 47-62 D-amino acid oxidase Homo sapiens 111-115 34736643-0 2022 Colorimetric quantification of sodium benzoate in food by using d-amino acid oxidase and 2D metal organic framework nanosheets mediated cascade enzyme reactions. Sodium Benzoate 31-46 D-amino acid oxidase Homo sapiens 64-84 34736643-1 2022 A rapid colorimetric method for detecting sodium benzoate in food products was established based on the d-amino acid oxidase (DAAO) and 2D metal organic framework (2D MOF) nanosheets mediated cascade enzyme reactions. Sodium Benzoate 42-57 D-amino acid oxidase Homo sapiens 104-124 34736643-1 2022 A rapid colorimetric method for detecting sodium benzoate in food products was established based on the d-amino acid oxidase (DAAO) and 2D metal organic framework (2D MOF) nanosheets mediated cascade enzyme reactions. Sodium Benzoate 42-57 D-amino acid oxidase Homo sapiens 126-130 34736643-3 2022 Secondly, sodium benzoate as a competitive inhibitor of DAAO, could influence the production of H2O2 in DAAO mediated oxidation reaction. Sodium Benzoate 10-25 D-amino acid oxidase Homo sapiens 56-60 34736643-3 2022 Secondly, sodium benzoate as a competitive inhibitor of DAAO, could influence the production of H2O2 in DAAO mediated oxidation reaction. Sodium Benzoate 10-25 D-amino acid oxidase Homo sapiens 104-108 35023557-0 2022 Effects of sodium benzoate, a D-amino acid oxidase inhibitor, on perceived stress and cognitive function among patients with late-life depression: A randomized, double-blind, sertraline- and placebo-controlled trial. Sodium Benzoate 11-26 D-amino acid oxidase Homo sapiens 30-50 35023557-3 2022 This study aims to compare sodium benzoate (a D-amino acid oxidase (DAAO) inhibitor and an indirect NMDAR enhancer), sertraline (a selective serotonin reuptake inhibitor), and placebo in the treatment of late-life depression. Sodium Benzoate 27-42 D-amino acid oxidase Homo sapiens 46-66 35023557-3 2022 This study aims to compare sodium benzoate (a D-amino acid oxidase (DAAO) inhibitor and an indirect NMDAR enhancer), sertraline (a selective serotonin reuptake inhibitor), and placebo in the treatment of late-life depression. Sodium Benzoate 27-42 D-amino acid oxidase Homo sapiens 68-72 31113277-1 2019 OBJECTIVE: Sodium benzoate, a D-amino acid oxidase (DAAO) inhibitor, improved cognitive function of early-phase Alzheimer"s disease (AD) after 24-week treatment. Sodium Benzoate 11-26 D-amino acid oxidase Homo sapiens 30-50 33406269-2 2021 Sodium benzoate (a D-amino acid oxidase [DAO] inhibitor) has been found to improve the cognitive function of patients with early-phase Alzheimer"s disease (AD) (mild AD or MCI). Sodium Benzoate 0-15 D-amino acid oxidase Homo sapiens 19-39 33406269-2 2021 Sodium benzoate (a D-amino acid oxidase [DAO] inhibitor) has been found to improve the cognitive function of patients with early-phase Alzheimer"s disease (AD) (mild AD or MCI). Sodium Benzoate 0-15 D-amino acid oxidase Homo sapiens 41-44 33406269-10 2021 CONCLUSION: The current study is the first to demonstrate that a DAO inhibitor, sodium benzoate herein, can alter brain activity as well as cognitive functions in the MCI individuals. Sodium Benzoate 80-95 D-amino acid oxidase Homo sapiens 65-68 32110025-2 2020 A 24-week study demonstrated that sodium benzoate, a D-amino acid oxidase (DAAO) inhibitor, surpassed placebo in improving cognitive function in early-phase Alzheimer"s disease; however, benzoate did not excel placebo in another 6-week study on BPSD. Sodium Benzoate 34-49 D-amino acid oxidase Homo sapiens 53-73 32110025-2 2020 A 24-week study demonstrated that sodium benzoate, a D-amino acid oxidase (DAAO) inhibitor, surpassed placebo in improving cognitive function in early-phase Alzheimer"s disease; however, benzoate did not excel placebo in another 6-week study on BPSD. Sodium Benzoate 34-49 D-amino acid oxidase Homo sapiens 75-79 31660823-6 2020 A recent randomized, double-blind, placebo-controlled clinical trial found that add-on sodium benzoate, a DAAO inhibitor, improved the clinical symptoms in patients with clozapine-resistant schizophrenia, possibly through DAAO inhibition (and thereby NMDAR activation) and antioxidation as well; additionally, sodium benzoate showed no obvious side effects, indicating the treatment is safe at the doses up to 2 g per day for 6 weeks. Sodium Benzoate 87-102 D-amino acid oxidase Homo sapiens 106-110 31660823-6 2020 A recent randomized, double-blind, placebo-controlled clinical trial found that add-on sodium benzoate, a DAAO inhibitor, improved the clinical symptoms in patients with clozapine-resistant schizophrenia, possibly through DAAO inhibition (and thereby NMDAR activation) and antioxidation as well; additionally, sodium benzoate showed no obvious side effects, indicating the treatment is safe at the doses up to 2 g per day for 6 weeks. Sodium Benzoate 87-102 D-amino acid oxidase Homo sapiens 222-226 31482779-8 2019 Therapies targeting residual positive symptoms/treatment-resistant schizophrenia include pimavanserin, dopamine D1/D2 antagonist LuAF-35700, and DAAO inhibitor sodium benzoate. Sodium Benzoate 160-175 D-amino acid oxidase Homo sapiens 145-149 31113277-1 2019 OBJECTIVE: Sodium benzoate, a D-amino acid oxidase (DAAO) inhibitor, improved cognitive function of early-phase Alzheimer"s disease (AD) after 24-week treatment. Sodium Benzoate 11-26 D-amino acid oxidase Homo sapiens 52-56 24089054-5 2013 Sodium benzoate is a d-amino acid oxidase inhibitor. Sodium Benzoate 0-15 D-amino acid oxidase Homo sapiens 21-41 29397899-4 2018 This study aimed to examine the efficacy and safety of a D-amino acid oxidase inhibitor, sodium benzoate, for schizophrenia patients who had poor response to clozapine. Sodium Benzoate 89-104 D-amino acid oxidase Homo sapiens 57-77 24074637-5 2014 This study examined the efficacy and safety of sodium benzoate, a D-amino acid oxidase inhibitor, for the treatment of amnestic mild cognitive impairment and mild AD. Sodium Benzoate 47-62 D-amino acid oxidase Homo sapiens 66-86 29893546-5 2018 However, in the clinical pilot studies using sodium benzoate, d-amino acids were not quantified to verify that sodium benzoate"s efficacy was mediated through DAAO inhibition. Sodium Benzoate 111-126 D-amino acid oxidase Homo sapiens 159-163 29893546-7 2018 We reasoned that the cerebral spinal fluid d-alanine quantity is reflective of the brain d-alanine levels and it would increase as a consequence of DAAO inhibition with sodium benzoate. Sodium Benzoate 169-184 D-amino acid oxidase Homo sapiens 148-152 26691576-2 2017 Sarcosine, a glycine transporter I (GlyT-1) inhibitor, and sodium benzoate, a d-amino acid oxidase (DAAO) inhibitor, can both enhance NMDA receptor-mediated neurotransmission. Sodium Benzoate 59-74 D-amino acid oxidase Homo sapiens 78-98 26691576-2 2017 Sarcosine, a glycine transporter I (GlyT-1) inhibitor, and sodium benzoate, a d-amino acid oxidase (DAAO) inhibitor, can both enhance NMDA receptor-mediated neurotransmission. Sodium Benzoate 59-74 D-amino acid oxidase Homo sapiens 100-104 21458638-0 2011 Determination of sodium benzoate by chiral ligand exchange CE based on its inhibitory activity in D-amino acid oxidase mediated oxidation of D-serine. Sodium Benzoate 17-32 D-amino acid oxidase Homo sapiens 98-118 21458638-1 2011 A novel quantitative approach for the determination of sodium benzoate (SB) was proposed by the kinetic study about its competitive inhibitory efficiency to D-amino acid oxidase (DAAO) activity with a chiral ligand exchange capillary electrophoresis (CE) method, in which the Zn(II)-L-prolinamide complex was chosen as a novel chiral selector. Sodium Benzoate 55-70 D-amino acid oxidase Homo sapiens 157-177 21458638-1 2011 A novel quantitative approach for the determination of sodium benzoate (SB) was proposed by the kinetic study about its competitive inhibitory efficiency to D-amino acid oxidase (DAAO) activity with a chiral ligand exchange capillary electrophoresis (CE) method, in which the Zn(II)-L-prolinamide complex was chosen as a novel chiral selector. Sodium Benzoate 55-70 D-amino acid oxidase Homo sapiens 179-183 21458638-1 2011 A novel quantitative approach for the determination of sodium benzoate (SB) was proposed by the kinetic study about its competitive inhibitory efficiency to D-amino acid oxidase (DAAO) activity with a chiral ligand exchange capillary electrophoresis (CE) method, in which the Zn(II)-L-prolinamide complex was chosen as a novel chiral selector. Sodium Benzoate 72-74 D-amino acid oxidase Homo sapiens 157-177 21458638-1 2011 A novel quantitative approach for the determination of sodium benzoate (SB) was proposed by the kinetic study about its competitive inhibitory efficiency to D-amino acid oxidase (DAAO) activity with a chiral ligand exchange capillary electrophoresis (CE) method, in which the Zn(II)-L-prolinamide complex was chosen as a novel chiral selector. Sodium Benzoate 72-74 D-amino acid oxidase Homo sapiens 179-183 21458638-3 2011 This chiral separation method was further used to observe DAAO activity through the determination of D-Serine concentration variation after being incubated with DAAO and obtain the sigmoidal inhibitory curve of SB to DAAO activity. Sodium Benzoate 211-213 D-amino acid oxidase Homo sapiens 58-62